『Malignant』のカバーアート

Malignant

How Bad Policy and Bad Evidence Harm People with Cancer

プレビューの再生

聴き放題対象外タイトルです。Audible会員登録で、非会員価格の30%OFFで購入できます。

¥1,750で会員登録し購入
無料体験で、20万以上の対象作品が聴き放題に
アプリならオフライン再生可能
プロの声優や俳優の朗読も楽しめる
Audibleでしか聴けない本やポッドキャストも多数
無料体験終了後は月額¥1,500。いつでも退会できます。

Malignant

著者: Vinayak K. Prasad
ナレーター: Vinayak K. Prasad
¥1,750で会員登録し購入

無料体験終了後は月額¥1,500。いつでも退会できます。

¥2,500 で購入

¥2,500 で購入

注文を確定する
下4桁がのクレジットカードで支払う
ボタンを押すと、Audibleの利用規約およびAmazonのプライバシー規約同意したものとみなされます。支払方法および返品等についてはこちら
キャンセル

このコンテンツについて

Each week, people read about new and exciting cancer drugs. Some of these drugs are truly transformative, offering major improvements in how long patients live or how they feel, but what is often missing from the popular narrative is that, far too often, these new drugs have marginal or minimal benefits. Some are even harmful.

In Malignant, hematologist-oncologist Dr. Vinayak K. Prasad discusses about the many sobering examples of how patients are too often failed by cancer policy and by how oncology is practiced.

Throughout this audiobook, Prasad illuminates deceptive practices, which:

  • Promote novel cancer therapies long before credible data are available to support such treatment
  • Exaggerate the potential benefits of new therapies, many of which cost thousands and in some cases hundreds of thousands of dollars

Prasad then critiques the financial conflicts of interest that pervade the oncology field, the pharmaceutical industry, and the US Food and Drug administration. This is a book about how the actions of human beings - our policies, our standards of evidence, and our drug regulation - incentivize the pursuit of marginal or unproven therapies at lofty and unsustainable prices.

He takes us through how cancer trials are conducted, how drugs come to market, and how pricing decisions are made, asking how we can ensure that more cancer drugs deliver both greater benefit and a lower price.

Ultimately, Prasad says:

  • More cancer clinical trials should measure outcomes that actually matter to people with cancer.
  • Patients on those trials should look more like actual global citizens.
  • We need drug regulators to raise, not perpetually lower, the bar for approval.
  • We need unbiased patient advocates and experts.

This well-designed, opinionated, and engaging audiobook explains what we can do differently to make serious and sustained progress against cancer and how we can avoid repeating the policy and practice mistakes of the past.

PLEASE NOTE: When you purchase this title, the accompanying PDF will be available in your Audible Library along with the audio.

©2020 Vinayak K. Prasad (P)2020 Vinayak K. Prasad
がん 政策・行政

Malignantに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。